35 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Ingenol analogs, pharmaceutical compositions and methods of use thereof
Glaxosmithkline Intellectual Property Development
Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators
Janssen Pharmaceutica
Processes and intermediates for preparing substituted hexahydrofuro [2,3-b] furans
Purdue Research Foundation
Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors
Katholieke Universiteit Leuven
Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.
Philipps-Universität Marburg
Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
Merck Sharp & Dohme
Amide compounds for treatment of complement mediated disorders
Achillion Pharmaceuticals
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.
Abbott Laboratories
Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8.
National Health Research Institutes
Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide.
Pfizer
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Novartis Pharmaceuticals
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
University of Auckland
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
Purdue University
Discovery and optimization of nonpeptide HIV-1 protease inhibitors.
Parke-Davis Pharmaceutical Research
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
Parke-Davis Pharmaceutical Research
Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.
Parke-Davis Pharmaceutical Research
Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase.
Sapienza University of Rome
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Merck Research Laboratories
2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.
Merck Sharp and Dohme Research Laboratories
Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
Parke-Davis Pharmaceutical Research
Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
Eli Lilly